Apollo Hospitals Enterprise (APH) delivered an in-line performance for the April-June quarter of the financial year 2024-2025 (Q1FY25)with growth in the number of patients. AHLL (Apollo Health & Lifestyle), a subsidiary, posted sales growth and profitability. APH also reduced operational costs at Healthco.
Analysts are expecting pharmaceutical companies to post sales growth of 10-11 per cent in the second quarter this financial year while the Ebitda (earnings before interest, tax, depreciation, and amortisation) margins are anticipated to improve by about 110 basis points. Ebitda improvement will be led by lower input costs because prices of active pharmaceutical ingredients (APIs) are 5-15 per cent lower year-on-year (Y-o-Y). Axis Capital said sales growth would be around 10 per cent, of which growth in the India market would be 11 per cent or so.
Excerpt from Shonali Sabherwal's The Love Diet
Excerpt from Shonali Sabherwal's The Love Diet
Kashmir is reeling under intense cold wave with minimum temperatures dropping to five degrees below the freezing point. The effect of the cold wave is compounded by equally severe power cuts and freezing of pipes carrying portable water. Mukhtar Ahmen reports.
The one-size-fits-all approach adopted by the AICTE is not suitable for regulating business schools in India, argues Asish K Bhattacharyya.
'LinkedIn is supposed to be this super-connected social media network for professionals that I reluctantly joined at the persistence of a former colleague appalled at my lack of self-promotion.' 'Well, I'm out there and I don't know who knows me, but I do know that LinkedIn's algorithm definitely doesn't,' says Kanika Datta.
